N/A
Completed N=774
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
Source: ClinicalTrials.gov NCT03169361 ↗Enrolled (actual)
774
Serious AEs
26.0%
Results posted
Dec 2023
Primary outcomePrimary: Number of Participants Reporting One or More Adverse Events (AEs) — 642 Participants
Summary
The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Reporting One or More Adverse Events (AEs) |
642 | — |
| PRIMARY Number of Participants Who Had One or More Adverse Drug Reactions (ADRs) |
573 | — |
Eligibility Criteria
Inclusion Criteria
- All patients who have been confirmed as administration of the drug.
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT03169361). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.